Cargando…

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes

Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puddu, Alessandra, Mach, François, Nencioni, Alessio, Viviani, Giorgio Luciano, Montecucco, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556837/ https://www.ncbi.nlm.nih.gov/pubmed/23365488 http://dx.doi.org/10.1155/2013/591056

Ejemplares similares

Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
por: Puddu, Alessandra, et al.
Publicado: (2013)

Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis
por: Sanguineti, Roberta, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Secreting Cell Function as well as Production of Inflammatory Reactive Oxygen Species Is Differently Regulated by Glycated Serum and High Levels of Glucose
por: Puddu, Alessandra, et al.
Publicado: (2014)

Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)
por: Puddu, Alessandra, et al.
Publicado: (2013)

Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15
por: Puddu, Alessandra, et al.
Publicado: (2015)

Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction
por: Puddu, Alessandra, et al.
Publicado: (2013)

Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes
por: Puddu, Alessandra, et al.
Publicado: (2014)

Role of Mitogen-Activated Protein Kinase Pathways in Multifactorial Adverse Cardiac Remodeling Associated with Metabolic Syndrome
por: Asrih, Mohamed, et al.
Publicado: (2013)

Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
por: Montecucco, Fabrizio, et al.
Publicado: (2012)

Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization
por: Puddu, Alessandra, et al.
Publicado: (2012)

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
por: Chang, Jui-Ting, et al.
Publicado: (2017)

Advanced Glycation End-Products and Hyperglycemia Increase Angiopoietin-2 Production by Impairing Angiopoietin-1-Tie-2 System
por: Puddu, Alessandra, et al.
Publicado: (2019)

Correction: Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
por: Chang, Jui-Ting, et al.
Publicado: (2023)

Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs) – induced apoptosis
por: Zhan, Yi, et al.
Publicado: (2012)

Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
por: Willard, Francis S., et al.
Publicado: (2012)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression
por: YI, BO, et al.
Publicado: (2014)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Oxaprozin-Induced Apoptosis on CD40 Ligand-Treated Human Primary Monocytes Is Associated with the Modulation of Defined Intracellular Pathways
por: Montecucco, Fabrizio, et al.
Publicado: (2009)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
por: Patel Chavez, Chandani, et al.
Publicado: (2021)

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
por: Grieco, Maddalena, et al.
Publicado: (2019)

Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes
por: Leung, Sherman S., et al.
Publicado: (2023)

New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor
por: Montecucco, Fabrizio, et al.
Publicado: (2008)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery
por: Salehi, Marzieh, et al.
Publicado: (2014)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Protective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage
por: Guo, Lixin, et al.
Publicado: (2015)

Direct cardiovascular effects of glucagon like peptide-1
por: Sheikh, Asfandyar
Publicado: (2013)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Equine glucagon-like peptide-1 receptor physiology
por: Kheder, Murad H., et al.
Publicado: (2018)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n5t2ivmhb7a16bqbr6ir5fvb5a